NewsSep 8, 2026
If you're on a first-line aromatase inhibitor plus a CDK4/6 inhibitor for HR-positive, HER2-negative metastatic breast cancer, there's a new option worth understanding. On September 4, 2026, the FDA approved camizestrant (Etcamah) as the first cancer therapy triggered by a blood test rather than a growing tumor on a scan. In the trial that won it approval, switching the moment an ESR1 mutation appeared in the blood roughly doubled the time before the cancer advanced. Whether it also extends life is what the next few years of follow-up will answer.
CancerSep 3, 2026
A 3D mammogram is still a mammogram, but it takes X-ray images from several angles and rebuilds the breast into thin slices, so overlapping tissue is less likely to hide a cancer or mimic one. In practice it usually finds a little more cancer, especially invasive tumors, and in U.S. clinics it often means fewer callbacks for a second look. What it hasn't yet clearly proven is that catching those extra cancers leads to fewer interval cancers, advanced cancers, or breast cancer deaths for most women. If 3D is available and covered, it's a reasonable choice; if only 2D is available or affordable, the mammogram you actually get on schedule matters far more than which machine takes it.
MedicationAug 30, 2026
Yes, for most adults with polycythemia vera who depend on regular phlebotomies, a newly approved once-weekly shot can replace them. The FDA cleared Mimrylo (rusfertide) on August 28, 2026. It's an add-on to standard care, not a cure, and hasn't yet been shown to prevent clots or extend life.
CancerAug 26, 2026
Yes. In the trial that led to its August 26, 2026 approval, daraxonrasib (Rasonque) roughly doubled median survival over standard chemotherapy in adults with previously treated metastatic pancreatic cancer. It's a once-daily pill that blocks mutant RAS, the mutation driving nearly every pancreatic tumor, so most patients qualify without special testing. It's easier to stay on than chemo. Resistance still comes. And the drug is expensive.
CancerAug 22, 2026
If your high-risk melanoma has been fully removed, a personalized mRNA vaccine may help keep it from coming back. In a phase 2b trial, adding intismeran autogene (formerly mRNA-4157 or V940) to pembrolizumab led to fewer recurrences and fewer distant metastases than pembrolizumab alone. On August 19, 2026, Moderna and Merck said the larger phase 3 trial met its recurrence and distant-metastasis endpoints. But the vaccine isn't approved, and its topline release gave no effect sizes or survival data. The proven move today is still standard adjuvant care after surgery.
NutritionAug 5, 2026
Ordinary diet-soda drinking hasn't been shown to cause cancer. In 2023, IARC called aspartame "possibly carcinogenic." The same year, JECFA, another WHO-linked committee, read much of the same evidence with one difference: it asked what happens at the amounts people actually consume, and left its daily intake limit where it was. IARC's label flags a possible hazard, not a proven risk at ordinary intake. The signals behind it are limited. Some observational studies report modest cancer associations, and the animal and mechanistic evidence has big gaps. What follows is what the evidence supports, where it's shaky, and who has reason to cut back.
Vitamin B12Jun 4, 2026
Vitamin B12 is an essential nutrient responsible for maintaining healthy nerve function, producing red blood cells, and supporting DNA synthesis. When the body lacks sufficient B12, a variety of symptoms can appear, including fatigue, cognitive changes, anemia, and neurological issues. These symptoms are typically attributed to nutritional causes or absorption problems. However, research has increasingly identified links between vitamin B12 deficiency and certain cancers, raising important questions about whether such a deficiency could sometimes be a sign of an undiagnosed malignancy.
Skin HealthJun 4, 2026
The nose is the single most common site on the face for non-melanoma skin cancer. It protrudes, it catches sun year-round, and its complex anatomy makes both removal and repair a challenge. But the research is clear on what determines whether nasal skin cancer comes back: clean surgical margins. When surgeons achieve clear margins, recurrence sits around 6%. With positive (incomplete) margins, it climbs to roughly 24%.
That fourfold gap makes the surgical approach one of the most consequential decisions in treatment, sometimes more so than the specific type of cancer itself.
Prostate CancerJun 4, 2026
Eligard, an injectable form of leuprolide acetate, pushes testosterone down to castrate levels in the vast majority of men with prostate cancer. But "vast majority" ranges from 94% to 98% with shorter dosing intervals, dropping to roughly 88–90% with the longest option. That gap is worth understanding if you or someone you care about is choosing between a shot every month versus every six months.
Eligard works as a GnRH agonist (gonadotropin-releasing hormone agonist), which essentially tricks the brain's hormonal signaling system into shutting down testosterone production. It uses a polymer gel called Atrigel that forms a small biodegradable implant under the skin, slowly releasing leuprolide over weeks or months depending on the formulation.
CancerJun 4, 2026
CA 19-9 is the most validated blood marker for pancreatic cancer, yet it catches only about 72–80% of symptomatic cases and flags plenty of people who don't have cancer at all. It's a genuinely useful tool in the right context, but it's also widely misunderstood. If your doctor ordered this test, or if a result came back high (or suspiciously normal), understanding what CA 19-9 can and can't tell you matters more than the number on the page.
CancerJun 4, 2026
The clinical trial that won Cologuard FDA approval enrolled 9,989 people, each of whom collected a stool sample at home before their colonoscopy. Not one of them was told to skip red meat, avoid raw broccoli, or stop their vitamin C beforehand. The same was true in the 20,176-person trial of the next-generation version of the test.
That isn't a study oversight. It's the entire point of how Cologuard is built. The test looks for things that only come from your own gut, not from your last meal, so dietary prep would be redundant.
Blood TestsJun 4, 2026
A high albumin-to-globulin (A/G) ratio is one of those lab results that tends to cause worry for no reason. Across a wide range of conditions, from stroke to cancer to heart disease, a higher A/G ratio consistently tracks with better outcomes, not worse ones. The research is surprisingly clear on this: if your A/G ratio is going to lean in one direction, high is almost always preferable to low.
That said, "high" is relative. The clinical context, your other lab values, and just how high we're talking about all matter. There is a narrow window where a very elevated A/G ratio could signal something worth investigating, but the threshold for concern is well above what most people see on their results.
CancerJun 4, 2026
Most people learn to watch for dark, irregularly shaped moles. Amelanotic melanoma skips that playbook entirely. It shows up pink, red, or skin-colored, carrying little to no visible pigment. That disguise is the core problem: clinicians misdiagnose it anywhere from 25% to 89% of the time, and lesions often sit on the skin for more than a year before anyone identifies them correctly.
The result is predictable and grim. By the time amelanotic melanoma gets a proper diagnosis, tumors tend to be thicker, more advanced, and associated with worse survival than their pigmented counterparts. The cancer itself isn't inherently more lethal. It just gets a massive head start.
CancerJun 4, 2026
The honest answer about stage 4 lung cancer survival is that it depends enormously on specifics most people never hear about until they're sitting in an oncologist's office. Median survival still lands somewhere between 7 and 12 months for many patients treated with standard chemotherapy alone. But certain combinations of tumor biology, treatment type, and patient fitness are pushing some people well past the 5-year mark. The distance between the worst-case and best-case scenarios has never been wider.
That spread matters. It means a single "average" number is almost misleading. What actually predicts where someone falls on that spectrum is the type of lung cancer, whether it carries specific genetic mutations, how many places it has spread, overall health, and which treatments are on the table.
CancerJun 4, 2026
The next-generation version of Cologuard catches roughly 94% of colorectal cancers from a single stool sample collected on your bathroom counter. That sentence sounds like marketing copy, but it comes from a meta-analysis of 55 studies comparing the multi-target stool DNA test against colonoscopy as the reference standard.
If your doctor has handed you a kit, or you ordered one yourself, the next question is mechanical. What do you actually do with this box? Below is the full set of Cologuard instructions, what each step is checking for, and what the evidence says about how the test performs when used the way it was designed to be used.
CancerJun 4, 2026
Stage 4 pancreatic cancer carries one of the hardest prognoses in oncology, with typical survival measured in months. But buried in those statistics is a wide range. Median overall survival sits at 3 to 11 months with current standard chemotherapy, yet some patients, particularly those with limited metastases, good physical health, and responsive tumors, live several years and occasionally reach long-term remission. The difference between the short end and the long end of that range is not luck. It maps to specific, identifiable factors.
Understanding which factors matter, and which treatments apply to which situations, is the most practical thing you can do with a stage 4 diagnosis. The research paints a clearer picture than most people expect.
Immune SystemJun 4, 2026
A low globulin result on routine blood work usually reflects low immunoglobulins, the antibodies your immune system uses to fight infections. The medical term is hypogammaglobulinemia. What makes this number tricky is the enormous range of possibilities behind it: it can be a transient blip that resolves on its own, or it can be the first sign of immune deficiency, protein loss, or a blood cancer. Context is everything.
In one large laboratory study, flagging low calculated globulin (below 16 g/L) and running follow-up tests uncovered a mix of primary immune deficiency, multiple myeloma, drug-related immune suppression, and cases of unexplained hypogammaglobulinemia that needed further evaluation. That single number on a lab printout opened very different doors depending on the person.
Immune SystemJun 4, 2026
A lump in your groin is alarming. But in one large biopsy series, most superficial lymph node samples taken from the groin and other sites turned out to be non-neoplastic: reactive hyperplasia, lymphadenitis, or tuberculosis, not cancer. That's the statistical reality. The clinical reality, though, is more nuanced. Inguinal lymph nodes sit at a crossroads where infections, inflammatory conditions, and certain cancers all converge, and telling them apart requires more than just feeling a bump.
These nodes are your lower body's immune checkpoint. Understanding what they drain, how fast they react, and when their enlargement actually signals something serious gives you a much better framework than simply panicking or ignoring them.
CancerJun 3, 2026
In the trial that won Cologuard FDA approval, the test found 92.3% of colorectal cancers and 42.4% of advanced precancerous polyps in nearly 10,000 average-risk adults. That single split tells you almost everything about how to think about it.
The test is excellent at catching cancer that already exists. It is much less reliable at finding the polyps that might quietly turn into cancer over the next decade.
That distinction matters because most colorectal cancer screening is really about removing precursors before they become anything serious. So "is Cologuard accurate?" depends on which question you are actually asking the test.
CancerJun 3, 2026
No study has reported a cancer risk signal for psyllium husk. Not in humans, not in animals, not in lab work. If you've been searching for a psyllium husk cancer warning, the research simply doesn't contain one. What it does contain is a growing body of experimental evidence suggesting psyllium may actually work against cancer, particularly in the colon. The real safety concerns are decidedly less dramatic, but still worth paying attention to.
That disconnect between fear and evidence is worth unpacking, because the actual risks of psyllium husk are the ones most people never think to ask about.
